Nuclear receptors in lipid metabolism: Targeting the heart of dyslipidemia

被引：189

作者：

Beaven, SW ^{[1
]}

Tontonoz, P

机构：

[1] Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA

[2] Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA

来源：

ANNUAL REVIEW OF MEDICINE | 2006年 / 57卷

关键词：

liver X receptors (LXRs); peroxisome proliferator-activated receptors (PPARs); atherosclerosis; diabetes; obesity; metabolic syndrome;

D O I：

10.1146/annurev.med.57.121304.131428

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Dyslipidemia is the sine qua non of atherosclerosis, but it is also strongly associated with the metabolic syndrome, obesity, diabetes, and fatty liver disease. The molecular basis for future therapies requires understanding the pivotal role of nuclear hormone receptors in lipid and inflammatory homeostasis. This review summarizes evidence that the liver X receptor (LXR) and peroxisome proliferator-activated receptor (PPAR) are key transcriptional regulators in lipid metabolism. Additionally, their effects on glucose homeostasis and inflammation make LXR and PPAR signaling networks attractive molecular targets for managing lipid-related diseases.

引用

页码：313 / 329

页数：19

共 104 条

[1] Dietary cholesterol fails to stimulate the human cholesterol 7α-hydroxylase gene (CYP7A1) in transgenic mice.
Agellon, LB
Drover, VAB
Cheema, SK
Gbaguidi, GF
Walsh, A
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (23) : 20131 - 20134
[2] Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice
Alberti, S
Schuster, G
Parini, P
Feltkamp, D
Diczfalusy, U
Rudling, M
Angelin, B
Björkhem, I
Pettersson, S
Gustafsson, JÅ
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (05) : 565 - 573
[3] Attie AD, 2001, J LIPID RES, V42, P1717
[4] Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia - A prospective, randomized, double-blind trial
Ballantyne, CM
Houri, J
Notarbartolo, A
Melani, L
Lipka, LJ
Suresh, R
Sun, S
LeBeaut, AP
Sager, PT
Veltri, EP
[J]. CIRCULATION, 2003, 107 (19) : 2409 - 2415
[5] PPARγ is required for placental, cardiac, and adipose tissue development
Barak, Y
Nelson, MC
Ong, ES
Jones, YZ
Ruiz-Lozano, P
Chien, KR
Koder, A
Evans, RM
[J]. MOLECULAR CELL, 1999, 4 (04) : 585 - 595
[6] Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension
Barroso, I
Gurnell, M
Crowley, VEF
Agostini, M
Schwabe, JW
Soos, MA
Maslen, GL
Williams, TDM
Lewis, H
Schafer, AJ
Chatterjee, VKK
O'Rahilly, S
[J]. NATURE, 1999, 402 (6764) : 880 - 883
[7] The mechanisms of action of PPARs
Berger, J
Moller, DE
[J]. ANNUAL REVIEW OF MEDICINE, 2002, 53 : 409 - 435
[8] Protective role of phospholipid oxidation products in endotoxin-induced tissue damage
Bochkov, VN
Kadl, A
Huber, J
Gruber, F
Binder, BR
Leitinger, N
[J]. NATURE, 2002, 419 (6902) : 77 - 81
[9] The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
Bodzioch, M
Orsó, E
Klucken, T
Langmann, T
Böttcher, L
Diederich, W
Drobnik, W
Barlage, S
Büchler, C
Porsch-Özcürümez, M
Kaminski, WE
Hahmann, HW
Oette, K
Rothe, G
Aslanidis, C
Lackner, KJ
Schmitz, G
[J]. NATURE GENETICS, 1999, 22 (04) : 347 - 351
[10] Increasing HDL cholesterol levels
Brewer, HB
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) : 1491 - 1494

← 1 2 3 4 5 6 7 8 9 10 →